Phase 2
Completed N=24
Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)
Source: ClinicalTrials.gov NCT00147966 ↗Enrolled (actual)
24
Serious AEs
8.3%
Results posted
Mar 2010
Primary outcomePrimary: American College of Rheumatology (ACR) 20 at Week 12 — 12 participants
Summary
Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY American College of Rheumatology (ACR) 20 at Week 12 |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Active rheumatoid arthritis
- Use of concomitant methotrexate
Exclusion Criteria
- Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than methotrexate
- Serious medical conditions that would preclude the use of the treating agent
Data sourced from ClinicalTrials.gov (NCT00147966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.